Impact of thymidylate synthase promoter and DNA repair gene polymorphisms on susceptibility to childhood acute lymphoblastic leukemia.

abstract：:To define the initial characteristics and prognostic factors of patients with conjunctival low-grade malignant lymphoma, all patients treated for low-grade lymphoma with initial conjunctival involvement were reviewed. Forty-nine cases were selected, including 45 cases with exclusive ophthalmologic conjunctival involve...

journal_title：Leukemia & lymphoma

authors： Meunier J,Lumbroso-Le Rouïc L,Dendale R,Vincent-Salomon A,Asselain B,Arnaud P,Némati F,Fourquet A,Desjardins L,Plancher C,Levy C,Chaoui D,Validire P,Decaudin D

更新日期：2006-07-01 00:00:00

abstract：:Bronchiolitis obliterans organizing pneumonia (BOOP) presents with fever, dyspnoea, pleuritic chest pain and hypoxia. The diagnosis can be made from radiological appearances on chest radiograph and CT scan correlated with histological findings following biopsy. We present a 52-year-old gentleman undergoing treatment f...

journal_title：Leukemia & lymphoma

authors： Macartney C,Burke E,Elborn S,Magee N,Noone P,Gleadhill I,Allen D,Kettle P,Drake M

更新日期：2005-10-01 00:00:00

abstract：:The Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway is active in both normal hematopoiesis and hematological malignancies. Moreover, Janus kinase-2 (JAK2) is the key hematopoietic kinase, and mutations together with single nucleotide polymorphisms (SNPs) of JAK2 have been thoroughly ev...

journal_title：Leukemia & lymphoma

authors： Zhong Y,Chen B,Feng J,Cheng L,Li Y,Qian J,Ding J,Gao F,Xia G,Chen N,Lu Z

更新日期：2010-06-01 00:00:00

abstract：:Six patients with Waldenström's macroglobulinemia (WM) resistant to previous 2-chlorodeoxyadenosine (2-CdA) therapy were treated with fludarabine. Both initial and subsequent therapy was administered according to the most widely used protocols. The median number of 2-CdA cycles given to the patients was 3.7 (range 2-5...

journal_title：Leukemia & lymphoma

authors： Lewandowski K,Halaburda K,Hellmann A

更新日期：2002-02-01 00:00:00

abstract：:Isolated myeloid sarcoma (MS) is a rare extramedullary presentation of acute myeloid leukemia (AML). Little is known about MS outcomes due to its rarity. A population-based analysis of MS using the Survival, Epidemiology, and End Results (SEER) database was performed. We identified 345 patients, aged 15 or older, diag...

journal_title：Leukemia & lymphoma

authors： Movassaghian M,Brunner AM,Blonquist TM,Sadrzadeh H,Bhatia A,Perry AM,Attar EC,Amrein PC,Ballen KK,Neuberg DS,Fathi AT

更新日期：2015-06-01 00:00:00

abstract：:Leukemic lymphoblasts in B-lineage acute lymphoblastic leukemia (ALL) express morphologic, phenotypic and genotypic features which resemble those of B lymphocyte progenitors in normal bone marrow. Normal immature B cells and cells from most cases of B-lineage ALL rapidly die in vitro unless they are supported by bone ...

journal_title：Leukemia & lymphoma

authors： Campana D,Coustan-Smith E,Kumagai MA,Manabe A

更新日期：1994-05-01 00:00:00

abstract：:Using a non-myeloablative stem cell trasplantation (NST) program, 25 allografts were prospectively given to 24 patients with acute myelogenous leukemia (AML) eligible for conventional allografting; 2 individuals had secondary forms of AML. The median age of the patients was 35 years, with a range of 12 to 56. All pati...

journal_title：Leukemia & lymphoma

authors： Ruiz-Argüelles GJ,Gómez-Almaguer D,David-Gomez-Rangel J,Vela-Ojeda J,Cantú-Rodríguez OG,Jaime-Pérez JC,González-Llano O,Herrera-Garza JL

更新日期：2004-06-01 00:00:00

abstract：:Hodgkin lymphoma (HL) has become a highly curable malignancy even in advanced stages when treated adequately. However, relapsed or refractory disease and treatment-related toxicity constitute a significant clinical challenge. Innovative approaches are thus needed to improve treatment of these mainly young patients. In...

journal_title：Leukemia & lymphoma

authors： Bröckelmann PJ,Borchmann P,Engert A

更新日期：2016-09-01 00:00:00

abstract：:Data on quality of life (QOL) specifically in maintenance therapy of acute lymphoblastic leukemia (ALL) are minimal. This study was done to assess various items listed in domains of QOL (physical, emotional, social and school health domains) of children with ALL during maintenance therapy, and compare the same with th...

journal_title：Leukemia & lymphoma

authors： Bansal M,Sharma KK,Vatsa M,Bakhshi S

更新日期：2013-05-01 00:00:00

abstract：:ZAP-70 has emerged as a protein of potential prognostic importance in chronic lymphocytic leukemia (CLL) following gene expression profiling which compared the 2 well established prognostic sub-sets, those with unmutated and mutated IgVH genes. This protein tyrosine kinase (PTK), known to be of importance in T and NK ...

journal_title：Leukemia & lymphoma

authors： Orchard J,Ibbotson R,Best G,Parker A,Oscier D

更新日期：2005-12-01 00:00:00

abstract：:Loss of cylindromatosis gene (CYLD) expression has been observed in various cancers, including chronic lymphocytic leukemia (CLL). As a deubiquitination enzyme, CYLD regulates the proliferation, development and activation of lymphoid cells. Here we determined the CYLD mRNA expression by quantitative polymerase chain r...

journal_title：Leukemia & lymphoma

authors： Wu W,Zhu H,Fu Y,Shen W,Xu J,Miao K,Hong M,Xu W,Liu P,Li J

更新日期：2014-03-01 00:00:00

abstract：:The tyrosine kinase inhibitors (TKIs), nilotinib, ponatinib, and dasatinib (but not bosutinib or imatinib), are associated with vascular adverse events (VAEs) in chronic myeloid leukemia (CML). Though the mechanism is inadequately understood, an effect on vascular cells has been suggested. We investigated the effect o...

journal_title：Leukemia & lymphoma

authors： Gover-Proaktor A,Granot G,Pasmanik-Chor M,Pasvolsky O,Shapira S,Raz O,Raanani P,Leader A

更新日期：2019-01-01 00:00:00

abstract：:Serum ferritin reflects body iron stores, but this correlation is dissociated in inflammation. Ferritin has been shown to be prognostically relevant in breast cancer and in patients with hematologic malignancies undergoing autologous or allogeneic stem cell transplantation. In the present study, we evaluated the progn...

journal_title：Leukemia & lymphoma

authors： Strasser-Weippl K,Ludwig H

更新日期：2014-11-01 00:00:00

abstract：:In order to clarify the relationship between myelodysplastic morphologic features of marrow cells and prognoses and 1.0 define other prognostic factors, 124 patients with the FAB criteria of myelodysplastic syndrome (MIX) were analysed. These included 57 patients with refractory anemia (RA), 5 RA with ring sideroblast...

journal_title：Leukemia & lymphoma

authors： Takahashi M,Koike T,Kishi K,Moriyama Y,Hayashi S,Shibata A

更新日期：1990-01-01 00:00:00

abstract：:Bone marrow mesenchymal stromal cells (MSCs) can rescue acute lymphoblastic leukemia (ALL) cells from L-asparaginase by replenishing the depleted asparagine. As both vincristine (VCR) and imatinib mesylate (IM) can inhibit MSCs' proliferation, we hypothesized that these drugs might reduce the niche support of MSCs to ...

journal_title：Leukemia & lymphoma

authors： Fung KL,Liang RH,Chan GC

更新日期：2010-03-01 00:00:00

abstract：:Recently, lenalidomide and low dose dexamethasone were found to result in superior overall survival compared to lenalidomide and high dose dexamethasone. The immune suppressive effects of dexamethasone can antagonize lenalidomide immunomodulatory activity and may explain this observation. We conducted a retrospective ...

journal_title：Leukemia & lymphoma

authors： Baz R,Patel M,Finley-Oliver E,Lebovic D,Hussein MA,Miller KC,Wood M,Sher T,Lee K,Chanan-Khan AA

更新日期：2010-06-01 00:00:00

abstract：:One possible reason for the relapse and refractoriness of extranodal natural killer/T-cell (NK/T) lymphoma (ENKL) is resistance to a CHOP-like regimen (cyclophosphamide, doxorubicin, vincristine, and prednisone). To evaluate the outcome of first-line EPOCH chemotherapy (etoposide, prednisone, vincristine, cyclophospha...

journal_title：Leukemia & lymphoma

authors： Huang H,Lin Z,Lin X,Cai Q,Xia Z,Jiang W

更新日期：2011-06-01 00:00:00

abstract：:We evaluated the safety and biologic activity of the BH3 mimetic protein, navitoclax, combined with rituximab, in comparison to rituximab alone. One hundred and eighteen patients with chronic lymphocytic leukemia (CLL) were randomized to receive eight weekly doses of rituximab (arm A), eight weekly doses of rituximab ...

journal_title：Leukemia & lymphoma

authors： Kipps TJ,Eradat H,Grosicki S,Catalano J,Cosolo W,Dyagil IS,Yalamanchili S,Chai A,Sahasranaman S,Punnoose E,Hurst D,Pylypenko H

更新日期：2015-01-01 00:00:00

abstract：:We evaluated outcome of 235 primary treatment failure (PTF) diffuse large B-cell lymphoma (DLBCL) patients based on salvage chemotherapy regimen and putative cell-of-origin (COO). Patients were divided into two groups; group A (n = 38) received high-dose cytarabine containing regimen, either DHAP or ESHAP. Patients in...

journal_title：Leukemia & lymphoma

authors： Badar T,Hamadani M,Bachanova V,Maddocks KJ,Umyarova E,Chavez JC,Epperla N,Chhabra S,Xavier AC,Karmali R,Salhab M,Reddy N,Glenn MJ,Hernandez-Ilizaliturri FJ,Flowers CR,Evens AM,Zhou Z,Lansigan F,Barta SK,Cohen JB,F

更新日期：2019-04-01 00:00:00

abstract：:Rituximab maintenance (RM) improves time to progression (PFS) in advanced follicular lymphoma (FL), but the impact of various RM schedules remains unknown. This study performed a retrospective evaluation of RM given for up to 2 years vs observation in 319 untreated FL patients (stage II-IV; grade 1-3A) responding to R...

journal_title：Leukemia & lymphoma

authors： Janikova A,Bortlicek Z,Campr V,Kopalova N,Benesova K,Hamouzova J,Belada D,Prochazka V,Pytlik R,Vokurka S,Pirnos J,Duras J,Mocikova H,Mayer J,Trneny M

更新日期：2016-05-01 00:00:00

abstract：:The aim of this research was to determine the serum dipeptidyl peptidase IV (DPPIV) activity as well as the percentages of CD26 + lymphocytes and CD26 + overall white blood cells in patients with hematological malignancies: non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), leukemia, plasmacytoma and multiple myeloma,...

journal_title：Leukemia & lymphoma

authors： Matić IZ,Đorđević M,Đorđić M,Grozdanić N,Damjanović A,Kolundžija B,Vidović A,Bila J,Ristić S,Mihaljević B,Tomin D,Milanović N,Ristić D,Purić M,Gavrilović D,Cordero OJ,Juranić ZD

更新日期：2013-12-01 00:00:00

abstract：:PTK787/ZK222584 (vatalanib), an orally active inhibitor of vascular endothelial growth factor receptors (VEGFRs), was evaluated in this phase II study of 20 patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Patients received once-daily PTK787/ZK222584 at a target dose of 1250 mg. Eighteen patien...

journal_title：Leukemia & lymphoma

authors： Brander D,Rizzieri D,Gockerman J,Diehl L,Shea TC,Decastro C,Moore JO,Beaven A

更新日期：2013-12-01 00:00:00

abstract：:We compared bcl-2 with P-glycoprotein expression (C494 and JSB1), and both with ex vivo chemosensitivity by Differential Staining Cytotoxicity (DiSC) assay (25 cytotoxic drugs), in 76 fresh haematological specimens, including 51 chronic lymphocytic leukaemias (CLL). Strong correlations were seen between bcl-2 and Pgp ...

journal_title：Leukemia & lymphoma

authors： Bosanquet AG,Bell PB,Burlton AR,Amos TA

更新日期：1996-12-01 00:00:00

abstract：:We report the case of a 77-year-old man who developed low grade B cell non-Hodgkin's lymphoma of the gastric stump 5 years after undergoing a distal gastrectomy for benign gastric ulcer. Lymphoma occurring in the post-operative stomach would appear to be very rare, with only 14 previously recorded cases. The median pe...

journal_title：Leukemia & lymphoma

authors： Di Cosimo S,Ferretti G,Partenzi A,Manicone AM,D'Aprile M

更新日期：2003-02-01 00:00:00

abstract：:There is no doubt that human B cell lymphoma does not elicit a clinically sufficient T cell mediated immune response that results in tumor rejection. However, the mechanisms leading to this lack of T cell recognition and effector function are still not fully understood. Many potential mechanisms such as "ignorance" in...

journal_title：Leukemia & lymphoma

authors： Schultze JL

更新日期：1999-01-01 00:00:00

abstract：:The immune cell composition of the follicular lymphoma (FL) tumor microenvironment is increasingly recognized as an important determinant for clinical outcome. Here, we explored frequency and distribution of dendritic cell (DC) subtypes in relation to regulatory T cells (Treg) by immunohistochemistry in lymph node bio...

journal_title：Leukemia & lymphoma

authors： Chevalier N,Mueller M,Mougiakakos D,Ihorst G,Marks R,Schmitt-Graeff A,Veelken H

更新日期：2016-09-01 00:00:00

abstract：:Patients with chronic lymphocytic lymphoma (CLL) with high-risk cytogenetics [del(11q)(q22.3) or del(17p)(p13.1)] have limited therapeutic options and their prognosis remains poor. This analysis was conducted to determine the clinical activity of lenalidomide in patients with high-risk disease. Relapsed/refractory pat...

journal_title：Leukemia & lymphoma

authors： Sher T,Miller KC,Lawrence D,Whitworth A,Hernandez-Ilizaliturri F,Czuczman MS,Miller A,Lawrence W,Bilgrami SA,Sood R,Wood MT,Block AW,Lee K,Chanan-Khan AA

更新日期：2010-01-01 00:00:00

abstract：:Safety testing for replication-competent retrovirus (RCR) is an important requirement in gene transfer clinical trials using retroviral vectors. A sensitive polymerase chain reaction (PCR) method is one approach to RCR detection. Only in the presence of RCR will the pol-env encoding sequences, necessary for viral repl...

journal_title：Leukemia & lymphoma

authors： Allan DS,De Koven A,Wild A,Kamel-Reid S,Dubé ID

更新日期：1996-10-01 00:00:00

abstract：:To explore the feasibility and potential advantages of PBSC in allogeneic transplantation, we grafted 24 patients (age 16-57, median 37) with different hematologic diseases (ALL = 10, AML = 5, MM = 4, NHL = 2, CML = 1, MDS = 1, AA = 1), 23 HLA-identical to their siblings and 1 partially matched. Cells were collected f...

journal_title：Leukemia & lymphoma

authors： Majolino I,Scime' R,Cavallaro AM,Santoro A,Catania P,Cannella S,Vasta S,Indovina A,Marceno' R

更新日期：1997-12-01 00:00:00

abstract：:The term high-risk multiple myeloma is aimed to identify a heterogeneous group of patients who are more likely to progress and die early of their disease. Therefore, recognition of these patients is crucial. With the increase in the number of treatment options, the outcome for high-risk patients has probably improved,...

journal_title：Leukemia & lymphoma

authors： Muchtar E,Magen H,Gertz MA

更新日期：2017-06-01 00:00:00